Researchers have launched a Phase 1 clinical trial to study nivolumab-IRDye800CW (nivo800), an innovative imaging agent designed to help surgeons more precisely visualize head and neck squamous cell carcinoma (HNSCC) tumors during surgery. The trial combines nivolumab, a well-known immunotherapy antibody, with IRDye800CW, a fluorescent dye, creating a tool that could potentially light up cancerous tissue in real time for surgical teams.
The study will enroll adults with biopsy-confirmed or presumed HNSCC who are already scheduled for standard-of-care surgical removal of their tumors. Participants will receive two intravenous infusions of the imaging agent before their operation — one about two to three weeks prior, and another just one to two days before surgery. This timing allows researchers to study how the compound distributes within tumor tissue and surrounding structures over different time windows.
Beyond simply testing safety, the trial has a valuable secondary goal: evaluating pathological response in surgically removed tissue. By examining residual tumor, fibrosis, necrosis, and immune cell activity (specifically tumor-infiltrating lymphocytes) in different dose groups, researchers hope to learn more about how the body responds to the combination agent at a cellular level. This kind of detailed analysis could offer broader insights into immune engagement with HNSCC tumors, a cancer type where improved visualization during surgery could support more complete tumor removal.
Fluorescence-guided surgery is an area of growing interest because it has the potential to give surgeons additional real-time visual information beyond what the eye alone can detect. If nivo800 proves safe and feasible in this early-phase study, it could pave the way for larger trials exploring whether this type of imaging approach helps improve surgical precision for head and neck cancer patients in the future.
This early-stage trial reflects the kind of methodical, safety-first research that underpins advances in cancer care. As with all Phase 1 studies, the primary focus is on safety and feasibility rather than definitive clinical benefit, and results will take time to emerge. This article is for informational purposes only and is not intended as medical advice.
Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.
Leave a Reply